Karolinska Development’s portfolio company Umecrine Cognition resumes patient inclusion in its Phase 1b/2a clinical study

Company Overview - Karolinska Development AB is a Nordic life sciences investment company focused on identifying breakthrough medical innovations in the Nordic region [3][4] - The company has a portfolio of eleven companies targeting innovative treatments for life-threatening or serious debilitating diseases [5] - Karolinska Development holds a 73% ownership stake in Umecrine Cognition, which is developing a new class of drugs for cognitive symptoms caused by liver disease [2] Clinical Trial Update - Umecrine Cognition has resumed patient inclusion in the clinical phase 1b/2a trial for the drug candidate golexanolone in patients with primary biliary cholangitis (PBC) [1] - The trial had been previously halted in March due to technical issues in capsule production, but this did not affect patient safety [1] Drug Development Focus - Golexanolone is being evaluated in a randomized, double-blind, placebo-controlled study aimed at patients with PBC who experience significant fatigue and cognitive symptoms [2]